Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-26-197577
Filing Date
2026-04-30
Accepted
2026-04-30 16:38:19
Documents
3
Period of Report
2026-06-17

Document Format Files

Seq Description Document Type Size
1 DEF 14A mink-def_14a_2026.htm DEF 14A 688842
2 GRAPHIC img69721585_0.jpg GRAPHIC 333665
3 GRAPHIC img69721585_1.jpg GRAPHIC 361762
  Complete submission text file 0001193125-26-197577.txt   1648008
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 212-994-8250
MiNK Therapeutics, Inc. (Filer) CIK: 0001840229 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-40908 | Film No.: 26926372
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)